<p>The FDA approved indications for amiodarone are recurrent ventricular fibrillation (VF)
and recurrent hemodynamically unstable ventricular tachycardia (VT). The FDA emphasizes that this drug should only be given in these conditions when they are clinically documented and have not responded to normal therapeutic doses of other antiarrhythmic agents, or when other drugs are not tolerated by the patient.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: CORDARONE (amiodarone HCl) tablets" href="#reference-L3561">18</a></sup></p><p>Off-label indications include atrial fibrillation and supraventricular tachycardia.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Freedman MD, Somberg JC: Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol. 1991 Nov;31(11):1061-9. doi: 10.1002/j.1552-4604.1991.tb03673.x. (PubMed ID 1753010)" href="#reference-A189666">7</a>,<a class="reference-popover-link" data-content="Rowland E, Krikler DM: Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias. Br Heart J. 1980 Jul;44(1):82-90. doi: 10.1136/hrt.44.1.82. (PubMed ID 7426165)" href="#reference-A189720">8</a>,<a class="reference-popover-link" data-content="Soult JA, Munoz M, Lopez JD, Romero A, Santos J, Tovaruela A: Efficacy and safety of intravenous amiodarone for short-term treatment of paroxysmal supraventricular tachycardia in children. Pediatr Cardiol. 1995 Jan-Feb;16(1):16-9. doi: 10.1007/BF02310328. (PubMed ID 7753695)" href="#reference-A189723">9</a>,<a class="reference-popover-link" data-content="AAFP: Medication Guide for Amiodarone" href="#reference-L11286">20</a></sup></p>